Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Combining antibody-drug conjugates with immunotherapy in solid tumors: current landscape and future perspectives
Eleonora Nicolò, Federica Giugliano, Liliana Ascione, et al.
Cancer Treatment Reviews (2022) Vol. 106, pp. 102395-102395
Closed Access | Times Cited: 124

Showing 1-25 of 124 citing articles:

Optimizing the safety of antibody–drug conjugates for patients with solid tumours
Paolo Tarantino, Biagio Ricciuti, Shan M. Pradhan, et al.
Nature Reviews Clinical Oncology (2023) Vol. 20, Iss. 8, pp. 558-576
Open Access | Times Cited: 119
Antibody–drug conjugates: in search of partners of choice
Jesús Fuentes‐Antrás, Sofia Genta, Abi Vijenthira, et al.
Trends in cancer (2023) Vol. 9, Iss. 4, pp. 339-354
Open Access | Times Cited: 118
The therapeutic window of antibody drug conjugates: A dogma in need of revision
Raffaele Colombo, Jamie R. Rich
Cancer Cell (2022) Vol. 40, Iss. 11, pp. 1255-1263
Open Access | Times Cited: 96
Antibody–Drug Conjugates: A Review of Approved Drugs and Their Clinical Level of Evidence
Pooja Gogia, Hamza Ashraf, S. Bhasin, et al.
Cancers (2023) Vol. 15, Iss. 15, pp. 3886-3886
Open Access | Times Cited: 86
A comprehensive overview on antibody-drug conjugates: from the conceptualization to cancer therapy
Federico Riccardi, Michele Dal Bo, Paolo Macor, et al.
Frontiers in Pharmacology (2023) Vol. 14
Open Access | Times Cited: 76
The Evolving Landscape of Antibody–Drug Conjugates: In Depth Analysis of Recent Research Progress
Janet M. Sasso, Rumiana Tenchov, Robert E. Bird, et al.
Bioconjugate Chemistry (2023) Vol. 34, Iss. 11, pp. 1951-2000
Open Access | Times Cited: 55
The promise and challenges of combination therapies with antibody-drug conjugates in solid tumors
Qing Wei, Peijing Li, Teng Yang, et al.
Journal of Hematology & Oncology (2024) Vol. 17, Iss. 1
Open Access | Times Cited: 54
Antibody-Drug Conjugates in Lung Cancer: Recent Advances and Implementing Strategies
Antonio Passaro, Pasi A. Jänne, Solange Peters
Journal of Clinical Oncology (2023) Vol. 41, Iss. 21, pp. 3747-3761
Closed Access | Times Cited: 52
A review of the clinical efficacy of FDA-approved antibody‒drug conjugates in human cancers
Kaifeng Liu, Meijia Li, Yudong Li, et al.
Molecular Cancer (2024) Vol. 23, Iss. 1
Open Access | Times Cited: 49
Disitamab vedotin (RC48) plus toripalimab for HER2-expressing advanced gastric or gastroesophageal junction and other solid tumours: a multicentre, open label, dose escalation and expansion phase 1 trial
Yakun Wang, Jifang Gong, Airong Wang, et al.
EClinicalMedicine (2024) Vol. 68, pp. 102415-102415
Open Access | Times Cited: 27
Antibody–Drug Conjugates: The Dynamic Evolution from Conventional to Next-Generation Constructs
Virginia Metrangolo, Lars H. Engelholm
Cancers (2024) Vol. 16, Iss. 2, pp. 447-447
Open Access | Times Cited: 26
The Journey of Antibody–Drug Conjugates: Lessons Learned from 40 Years of Development
Raffaele Colombo, Paolo Tarantino, Jamie R. Rich, et al.
Cancer Discovery (2024) Vol. 14, Iss. 11, pp. 2089-2108
Closed Access | Times Cited: 19
Diverse drug delivery systems for the enhancement of cancer immunotherapy: an overview
Xu Liu, Cheng Yang, Yao Mu, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access | Times Cited: 16
Overcoming cancer therapy resistance: From drug innovation to therapeutics
Jinrui Wei, Meng‐Yi Lu, Tian‐Hua Wei, et al.
Drug Resistance Updates (2025) Vol. 81, pp. 101229-101229
Closed Access | Times Cited: 2
The evolving therapeutic landscape of trastuzumab-drug conjugates: Future perspectives beyond HER2-positive breast cancer
Claudia von Arx, Pietro De Placido, Aldo Caltavituro, et al.
Cancer Treatment Reviews (2022) Vol. 113, pp. 102500-102500
Closed Access | Times Cited: 63
Overcoming Resistance to HER2-Directed Therapies in Breast Cancer
Ilana Schlam, Paolo Tarantino, Sara M. Tolaney
Cancers (2022) Vol. 14, Iss. 16, pp. 3996-3996
Open Access | Times Cited: 47
The HER2-low revolution in breast oncology: steps forward and emerging challenges
Eleonora Nicolò, Luca Boscolo Bielo, Giuseppe Curigliano, et al.
Therapeutic Advances in Medical Oncology (2023) Vol. 15
Open Access | Times Cited: 39
Immunotherapy for Metastatic Triple Negative Breast Cancer: Current Paradigm and Future Approaches
Veerle Geurts, Marleen Kok
Current Treatment Options in Oncology (2023) Vol. 24, Iss. 6, pp. 628-643
Open Access | Times Cited: 36
Antibody–Drug Conjugates in Breast Cancer: Current Status and Future Directions
Cynthia Mark, Jin Sun Lee, Xiaojiang Cui, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 18, pp. 13726-13726
Open Access | Times Cited: 33
HER2-targeting antibody–drug conjugate RC48 alone or in combination with immunotherapy for locally advanced or metastatic urothelial carcinoma: a multicenter, real-world study
Meiting Chen, Kai Yao, Manming Cao, et al.
Cancer Immunology Immunotherapy (2023) Vol. 72, Iss. 7, pp. 2309-2318
Open Access | Times Cited: 26
Antibody drug conjugates as targeted cancer therapy: past development, present challenges and future opportunities
Ritwik Maiti, Bhumika Patel, Nrupesh Patel, et al.
Archives of Pharmacal Research (2023) Vol. 46, Iss. 5, pp. 361-388
Open Access | Times Cited: 26
Cell death pathways: molecular mechanisms and therapeutic targets for cancer
Shaohui Wang, Sa Guo, Jing Guo, et al.
MedComm (2024) Vol. 5, Iss. 9
Open Access | Times Cited: 14
Homogeneous multi-payload antibody–drug conjugates
Toby Journeaux, Gonçalo J. L. Bernardes
Nature Chemistry (2024) Vol. 16, Iss. 6, pp. 854-870
Closed Access | Times Cited: 13
Targeting TACC3 Induces Immunogenic Cell Death and Enhances T-DM1 Response in HER2-Positive Breast Cancer
Mustafa Emre Gedik, Özge Saatci, Nathaniel Oberholtzer, et al.
Cancer Research (2024) Vol. 84, Iss. 9, pp. 1475-1490
Open Access | Times Cited: 12
Immune Checkpoint Inhibitors Rechallenge in Non-Small Cell Lung Cancer: Current Evidence and Future Directions
Xiaoyu Gang, Jinshan Yan, Xin Li, et al.
Cancer Letters (2024) Vol. 604, pp. 217241-217241
Open Access | Times Cited: 12
Page 1 - Next Page

Scroll to top